Managing Hypogonadism in Older Men: Is Testosterone Therapy the Answer?
DOI:
https://doi.org/10.12775/QS.2025.48.67040Keywords
Testosterone, Aging men, Hypogonadism, Testosterone replacement therapy, Bone density, ErythrocitosisAbstract
Introduction:
Age-related decline in testosterone production contributes to late-onset hypogonadism (LOH), characterized by reduced muscle mass, bone density, and sexual function. The increasing use of testosterone replacement therapy (TRT) in aging men has raised concerns about its efficacy and safety. This review summarizes current evidence regarding the benefits and risks of TRT in older men.
Material and Methods:
A literature review was performed in PubMed, Scopus, Cochrane Library, and Web of Science, including studies from 2015–2025. Clinical trials, meta-analyses, and reviews on the effects of TRT on body composition, bone density, metabolic profile, sexual and cognitive function, cardiovascular health, and prostate safety were analyzed.
Results:
TRT improves lean body mass, reduces visceral fat, and enhances bone mineral density, especially in the lumbar spine. Moderate benefits are seen in sexual desire and erectile function, with no significant cognitive improvement. The most frequent adverse effect is erythrocytosis. Prostate safety appears acceptable when physiological testosterone levels are maintained.
Conclusion:
TRT can provide functional and metabolic benefits in older hypogonadal men but requires careful selection, individualized dosing, and regular monitoring due to potential hematologic and cardiovascular risks.
References
1. Galbiati FF, Goldman AL, Gattu A, Guzelce EC, Bhasin S. Benefits and Risks of Testosterone Treatment of Older Men with Hypogonadism. Urologic Clinics of North America. 2022;49(4),593‑602. doi: https://doi.org/10.1016/j.ucl.2022.07.011.
2. McBride JA, Carson CC III, Coward RM. Testosterone deficiency in the aging male. Therapeutic Advance in Urology. 2016;8(1):47-60. doi: https://doi.org/10.1177/1756287215612961.
3. Barbonetti A, D’Andrea S, Francavilla S. Testosterone replacement therapy. Andrology. 2020;8(6):1551-1566. doi: https://doi.org/10.1111/andr.12774.
4. Yabluchanskiy A, Tsitouras PD. Is Testosterone Replacement Therapy in Older Men Effective and Safe? Drug & Aging. 2019;36:981-989. doi: https://doi.org/10.1007/s40266-019-00716-2.
5. Yeap BB, Tran C, Douglass CM, McNeil JJ. Testosterone Therapy in Older Men: Present and Future Considerations. Drugs & Aging. 2025;42;501-512. doi: https://doi.org/10.1007/s40266-025-01209-1.
6. Ide H. The impact of testosterone in men’s health. Endocrine Journal. 2023;70(7), 655-662. doi: https://doi.org/10.1507/endocrj.EJ22-0604.
7. Green DJ, Chasland LC, Yeap BB, Naylor LH. Comparing the Impacts of Testosterone and Exercise on Lean Body Mass, Strength and Aerobic Fitness in Aging Men. Sport Medicine - Open. 2024;10 doi: https://doi.org/10.1186/s40798-024-00703-x.
8. Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nature Review Endocrinology. 2018;14(9):513-537. doi: https://doi.org/10.1038/s41574-018-0062-9.
9. Barone, B., Napolitano, L., Abate, M., Cirillo, L., et.al. The Role of Testosterone in the Elderly: What do We Know? International Journal of Molecular Sciences. 2022; 23(7):3535. doi: https://doi.org/10.3390/ijms23073535.
10. Rosenberg EA, Buzkova P, Fink HA, Robbins JA, Shores MM, Matsumoto AM, Mukamal KJ. Testosterone, Dihydrotestosterone, Bone Density, and Hip Fracture Risk among Older Men: The Cardiovascular Health Study. Metabolism. 2021; 114:154399. doi: https://dx.doi.org/10.1016/j.metabol.2020.154399.
11. Snyder PJ, Bhasin S, Cunningham GR, Matsumoto AM, Stephans-Shields AJ, Cauley JA, Gill TM. Effects of Testosterone Treatment in Older Men. 2016;373:611-624. doi: https://doi.org/10.1056/NEJMoa1506119.
12. Snyder PJ. Lessons From the Testosterone Trials. Endocrine reviews. 2018;39(3):369-386. doi: https://doi.org/10.1210/er.2017-00234.
13. Kaufman JM, Lapauw B. Role of testosterone in cognition and mobility of aging men. Andrology. 2020;8(6):1567-1579. doi: https://doi.org/10.1111/andr.12872.
14. Mohler III, E.R., Ellenberg, S.S., Lewis, C.E., et al. The Effect of Testosterone on Cardiovascular Biomarkers in Testosterone Trials. 2017;103(2):681-688. doi: https://doi.org/10.1210/jc.2017-02243.
15. Wittert G, Grossmann M. Obesity, type 2 diabetes, and testosterone in aging men. Reviews in Endocrine & Metabolic Disorders. 2022;23:1233-1242. doi: https://doi.org/10.1007/s11154-022-09746-5.
16. Wittert GA, Robledo KP, Handelsman DJ, et al. Testosterone Treatment and Sexual Function in Men: Secondary Analysis of the T4DM(Testosterone for Diabetes) Trial. The Journal of Clinical Endocrinology & Metabolism. 2025;110(7):2157-2170. doi: https://doi.org/10.1210/clinem/dgaf060.
17. Ohlander SJ, Varghese B, Pastuszek AW. Erythrocytosis Following Testosterone Therapy. Sexual Medicine Reviews. 2018;6(1):77-85. doi: https://doi.org/10.1016/j.sxmr.2017.04.001.
18. Bond P, Verdegaal T, Smit DL. Testosterone therapy-induced erythrocytosis: can phlebotomy be justified? Endocrine Connections. 2024;13(10):e240283. doi: https://doi.org/10.1530/EC-24-0283.
19. Thompson K, Osorio LG, Mughni S, Jordan J, Oyesanmi. An Interesting Presentation of Testosterone-Induced Arterial Thrombosis. Cureus. 2021;13(5):e14972. doi: https://doi.org/10.7759/cureus.14972
20. Bhasin S, et.al. Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of TRAVERSE study. American Heart Journal. 2022;245:41-50. doi: https://doi.org/10.1016/j.ahj.2021.11.016.
21. Bhasin S, et.al. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism. JAMA Netw Open. 2023;6(12):e2348692. doi: https://doi.org/10.1001/jamanetworkopen.2023.48692.
22. Laouali N, et.al. Testosterone and All-Cause Mortality in Old Men: The Role of Metabolic Syndrome. Journal of the Endocrine Society. 2018;2(4):322-335. doi: https://doi.org/10.1210/js.2018-00005.
23. Hermoso DAM, Bizerra PFV, Constantin RP, Ishii-Iwamoto EL, Gilglioni EH. Association between metabolic syndrome, hepatic stenosis, and testosterone deficiency: evidences from studies with men and rodents. 2020;23(5):1296-1315. doi: https://doi.org/10.1080/13685538.2020.1764927.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Julita Jagodzińska, Martyna Grześkowiak, Agata Juchniewicz, Jakub Sapikowski, Maria Janiszewska, Iga Kuba, Jakub Idziński, Anna Lubomska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 19
Number of citations: 0
